Other
Peutz-Jeghers Syndrome
3
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Peutz-Jeghers syndrome is an early-stage landscape with 3 programs across 2 companies. The most active players are Novartis, Maastricht Radiation Oncology. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Phase 3
No programs
Analysis
Trial Status
4
clinical trials
Terminated1 · 25%
Unknown status1 · 25%
Withdrawn1 · 25%
Recruiting1 · 25%
Clinical Trials
Trial Activity
Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
Withdrawn·—·Phase 2·NCT01178151
Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome
Recruiting·—·N/A·NCT06722534·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)